Academic Unit of Obstetrics and Gynaecology, University of Manchester, St Mary's Hospital, Manchester, UK.
Int J Hyperthermia. 2012;28(6):478-88. doi: 10.3109/02656736.2012.677934. Epub 2012 Jun 12.
The discovery that human papillomavirus (HPV) is the necessary causal factor in cervical carcinogenesis has made it a target for prophylactic and therapeutic vaccines, as well as a diagnostic tool in cervical screening. Whilst prophylactic vaccination has proven very effective in terms of preventing cervical cancer precursor lesions, therapeutic strategies have presented far greater challenges. HPV testing has shown itself to be extremely valuable in the triage of low grade cytological abnormalities, test of cure following treatment of cervical intraepithelial neoplasia (CIN), and will, over the next 10 years, gradually replace cytology as the mainstay of primary cervical screening. In this review, the latest evidence supporting HPV as both a biomarker of risk for cervical cancer and a target for prophylactic and therapeutic vaccination is presented.
人乳头瘤病毒（HPV）是宫颈癌发生的必要因果因素，这一发现使其成为预防性和治疗性疫苗的目标，也是宫颈筛查的诊断工具。虽然预防性疫苗在预防宫颈癌前病变方面已被证明非常有效，但治疗策略却带来了更大的挑战。HPV 检测在对低级别细胞学异常进行分流、治疗宫颈上皮内瘤变（CIN）后的疗效检测以及在未来 10 年内逐渐取代细胞学成为宫颈癌初级筛查的主要手段方面表现出极高的价值。本综述介绍了支持 HPV 作为宫颈癌风险的生物标志物和预防性及治疗性疫苗靶点的最新证据。
